Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Willis

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Annals of Neurology|November 17, 2023
Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real-World CohortKarim L Kreft, Emeka Uzochukwu, Sam Loveless, et al.
Practical Neurology|July 21, 2022
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guidelineMarija Cauchi, Mark Willis, Angela Andrews, et al.
The Journal of Clinical Endocrinology and Metabolism|June 8, 2018
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological FeaturesNadia Pariani, Mark Willis, Ilaria Muller, et al.
Thyroid : Official Journal of the American Thyroid Association|October 24, 2018
Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many YearsIlaria Muller, Mark Willis, Sarah Healy, et al.
Cancers|December 30, 2025
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare SystemBenjamin Schroeder, Prakrit Prasad, Ope Gbadegesin, et al.
Practical Neurology|January 6, 2026
CAR-T cells in the treatment of neurological autoimmune diseasesFrederick W Vonberg, Benjamin E Schroeder, Amy Edwards, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosisEmma C Tallantyre, Martin J Scurr, Nicola Vickaryous, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccinationSafiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Annals of Neurology|October 23, 2021
COVID-19 Vaccine Response in People with Multiple SclerosisEmma C Tallantyre, Nicola Vickaryous, Valerie Anderson, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Annals of Neurology|November 17, 2023
Relevance of Multiple Sclerosis Severity Genotype in Predicting Disease Course: A Real-World CohortKarim L Kreft, Emeka Uzochukwu, Sam Loveless, et al.
Practical Neurology|July 21, 2022
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guidelineMarija Cauchi, Mark Willis, Angela Andrews, et al.
The Journal of Clinical Endocrinology and Metabolism|June 8, 2018
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological FeaturesNadia Pariani, Mark Willis, Ilaria Muller, et al.
Thyroid : Official Journal of the American Thyroid Association|October 24, 2018
Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many YearsIlaria Muller, Mark Willis, Sarah Healy, et al.
Cancers|December 30, 2025
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare SystemBenjamin Schroeder, Prakrit Prasad, Ope Gbadegesin, et al.
Practical Neurology|January 6, 2026
CAR-T cells in the treatment of neurological autoimmune diseasesFrederick W Vonberg, Benjamin E Schroeder, Amy Edwards, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosisEmma C Tallantyre, Martin J Scurr, Nicola Vickaryous, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccinationSafiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Annals of Neurology|October 23, 2021
COVID-19 Vaccine Response in People with Multiple SclerosisEmma C Tallantyre, Nicola Vickaryous, Valerie Anderson, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Pageof 4